[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sarcopenia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sarcopenia":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,225,0,25,[9,52,79,114,144,187,215,234,264,285,313,334,355,381,401,421,451,480,509,532,557,580,601,620,644],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100639336","effects-of-aquatic-exercise-in-older-adults-with-sarcopeniaa-randomized-trial-100639336",false,"NCT07575958","Effects of Aquatic Exercise in Older Adults With Sarcopenia:A Randomized Trial","Effects of Aquatic Exercise Program on Muscle Strength, Muscle Mass, Physical Performance and Quality of Life in Older Adults With Sarcopenia: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥65 years\n2. Diagnosis of \"definite sarcopenia\" according to the ISarcoPRM diagnostic algorithm\n3. Not receiving nutritional supplementation and not requiring nutritional support according to the Mini Nutritional Assessment (MNA)\n4. Sufficient cognitive ability to understand and follow instructions, including study-related questions and the home exercise program\n5. Voluntary participation in the study\n6. Ability to ambulate independently (assistive devices such as a cane are allowed; however, fully dependent individuals will be excluded)\n\nExclusion Criteria:\n\n1. Inability to complete assessment tests and questionnaires\n2. Presence of severe systemic disease that may contraindicate exercise\n3. Severe visual or hearing impairment\n4. Presence of a cardiac pacemaker\n5. Severe cardiopulmonary disease\n6. Uncontrolled hypertension\n7. Uncontrolled diabetes mellitus\n8. Receiving nutritional supplementation\n9. Severe anemia\n10. Conditions contraindicating hydrotherapy, including aquaphobia (fear of water), behavioral disorders, dyspnea at rest, urinary or fecal incontinence, known chlorine allergy, open wounds, acute systemic illness, epilepsy, tracheostomy, indwelling drainage devices, and immunodeficiency","ALL","65 Years",{"count":20,"type":21},44,"ESTIMATED","INTERVENTIONAL",[24],"NA","Sarcopenia is a geriatric syndrome characterized by age-related loss of skeletal muscle mass, strength, and physical performance, leading to increased risk of falls, functional decline, and reduced quality of life. Exercise interventions, particularly resistance training, are effective in managing sarcopenia; however, land-based exercises may be challenging for older adults due to balance impairments, joint problems, and fear of falling.\n\nPool-based exercise programs may offer a safe and feasible alternative, as water buoyancy reduces joint loading while providing resistance to support muscle strengthening. Despite these potential benefits, evidence regarding the effects of aquatic exercise in individuals with sarcopenia remains limited, especially in Türkiye.\n\nThis study aims to evaluate the effects of a 6-week supervised pool-based exercise program on muscle strength, muscle morphology, physical performance, mood, and quality of life in individuals aged 65 years and older with sarcopenia. Sarcopenia will be identified using the Sonographic Thigh Adjustment Ratio (STAR), based on ultrasound measurements of anterior thigh muscle thickness. In addition, appendicular skeletal muscle mass will be assessed using bioelectrical impedance analysis (ASM\u002Fheight²).\n\nOutcome measures will include ultrasound-based muscle thickness, STAR, muscle strength, functional performance tests, depressive symptoms, and health-related quality of life. Assessments will be performed at baseline, immediately after the intervention, and at 1-month follow-up.",[27,28],"Sarcopenia","Sarcopenia in Elderly",[30,31,32,33,34,35,36,37,38],"sarcopenia","aquatic exercise","hydrotherapy","aquatic therapy","sarcopenia ultrasound","Geriatric","Elderly","water-based exercise","Sonographic Thigh Adjustment Ratio(STAR)","RECRUITING","2026-08-17",{"date":42,"type":43},"2026-08-18","ACTUAL",{"date":45,"type":43},"2026-04-01",{"date":47,"type":21},"2026-12",{"name":49,"class":50},"Gaziosmanpasa Research and Education Hospital","OTHER_GOV",2,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100651614","sarcopenia-in-acute-ischemic-stroke-100651614","NCT07764172","Sarcopenia in Acute Ischemic Stroke","Sarcopenia in Patients During the Acute Phase of Ischemic Stroke: Multimodal Assessment and Three-Month Functional Outcomes","Inclusion Criteria:\n\n* Age 50 years and older\n* Acute ischemic stroke confirmed by CT or MRI\n* Admission within the first 72 hours\n* Written informed consent and availability of a contact telephone number for follow-up\n\nExclusion Criteria:\n\n* TIA without a visible lesion on neuroimaging; bilateral hemiparesis\n* Amputations or severe contractures that preclude anthropometric assessment\n* Active cancer at stage IV or life expectancy of less than 3 months\n* Neuromuscular diseases; chronic use of systemic glucocorticoids for more than 3 months\n* Pregnancy; refusal to participate\n\nDiscontinuation criteria (drop-out)\n\n* Discharge or death within the first 7 days\n* Withdrawal of consent\n* Transfer to another facility resulting in loss of contact","50 Years",{"count":61,"type":21},400,"OBSERVATIONAL","The objective of this observational study is to determine the prevalence of sarcopenia in patients aged 50 years and older with acute ischemic stroke, to characterize its trajectory during the acute phase using instrumental verification and functional-cognitive assessments, and to evaluate its impact on functional outcome at three months. The main research question is:\n\nIs the presence of sarcopenia at admission associated with less favorable stroke outcomes, including higher rates of complications and mortality?\n\nParticipants receiving standard medical care for acute ischemic stroke will undergo extended functional assessment for sarcopenia, and a subset will additionally undergo cognitive evaluation.",[27,65],"Acute Stroke",[30,67],"acute stroke","2026-08-12",{"date":70,"type":43},"2026-08-13",{"date":72,"type":21},"2026-08",{"date":74,"type":21},"2029-12-31",{"name":76,"class":77},"University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)","OTHER",1,{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":89,"studyType":62,"phases":4,"briefSummary":90,"conditions":91,"keywords":100,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":78},"100568904","cognitive-impact-associated-with-surgery-for-gastric-or-esophageal-cancer-100568904","NCT06687291","Cognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer","CASE","Inclusion Criteria:\n\n* Patients diagnosed with esophageal or gastric cancer, treated with (or without) chemotherapy and surgery.\n* Age ≥18 at the time for inclusion.\n* Participate on a voluntary basis and can (for any reason) end its participation during the study.\n* Capable of giving informed consent.\n\nExclusion Criteria:\n\n* Patients with preoperative cognitive dysfunction such as dementia.\n* Patients who are inoperable due to metastases.\n* Patients unable to communicate due to severely impaired hearing and\u002For - seeing.\n* Patients with ongoing drug and\u002For alcohol abuse.\n* Patients who cannot give informed consent.","18 Years",{"count":88,"type":21},130,"6 Months","The primary objective of this observational study is to investigate the incidence of Post Operative Delirium (POD) after gastroesophageal cancer surgery. Secondary objectives are to investigate the relationship between POD, preoperative depression, frailty, quality of life, malnutrition and sarcopenia.\n\nParticipants identified with POD will be asked (at the routine follow-up meeting after surgery) to participate in an qualitative interview, in order to understand the participant's experience of postoperative delirium.\n\nThe main objective aims to answer:\n\nWhat is the incidence of POD after gastroesophageal cancer surgery.",[92,93,94,95,96,27,97,98,99],"Gastroesophageal Cancer (GC)","Postoperative Delirium (POD)","Quality of Life (QOL)","Frailty","Malnutrition","Chemobrain","Chemotherapy","Depression",[101,102,95,103,104,96,27,97,98],"postoperative delirium","gastroesophageal cancer","Quality of life","Preoperative depression","2026-08-10",{"date":107,"type":43},"2026-08-11",{"date":109,"type":43},"2025-02-13",{"date":111,"type":21},"2028-11-11",{"name":113,"class":77},"Karolinska Institutet",{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":131,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":78},"100620441","effects-of-rehabilitative-exergame-training-on-foot-muscle-activity-balance-and-mobility-in-older-adults-100620441","NCT07357662","Effects of Rehabilitative Exergame Training on Foot Muscle Activity, Balance, and Mobility in Older Adults","Evaluation of the Effects of Rehabilitative Exergame Exercises on Foot Muscle Activation, Balance, and Mobility in Older Adults Using Surface Electromyography and Postural Sway Measurements","EXG-FOOT","Inclusion Criteria:\n\n* Aged 65 to 80 years\n* Having a minimum of 5 years of formal education\n* Ability to walk independently for at least 10 meters, with or without a walking aid if necessary\n* Having sufficient cognitive function for communication and participation, defined as a Mini-Mental State Examination (MMSE) score ≥26\n\nExclusion Criteria:\n\n* Body mass index (BMI ≥30 kg\u002Fm²)\n* Presence of central or peripheral nervous system disorders or use of medications that may affect balance\n* History of vestibular pathology\n* Lower extremity amputation, prior lower extremity surgery, or malignancy affecting the lower extremities\n* Presence of moderate to severe congenital heart disease, coronary artery disease, or cerebrovascular disease\n* Presence of visual, psychiatric, or cognitive impairments that could interfere with study participation or assessment procedures","80 Years",{"count":124,"type":21},40,[24],"This study is designed as a randomized controlled trial. A total of 40 healthy older adults residing in private and public nursing homes and rehabilitation centers in Mersin will be enrolled. Participants will be randomly assigned to either the intervention group (Group 1) or the control group (Group 2).\n\nThe intervention group will receive rehabilitative interactive game-based exercise training, while the control group will receive functional balance exercise training. Both groups will participate in exercise sessions three times per week, with each session lasting 40 minutes, over a period of 8 weeks.\n\nParticipants will undergo pre- and post-intervention assessments, including:\n\ni) clinical tests and measurements for cognitive, functional, and balance evaluation; ii) surface electromyography (sEMG) measurements recorded during the Functional Reach Test (FRT); and iii) biomechanical measurements obtained via integrated inertial measurement unit (IMU) sensors (accelerometer and gyroscope) and the Becure game board.\n\nElectrophysiological and biomechanical data will be analyzed using statistical comparisons, correlation analyses, and regression models. Variables derived from time, frequency, and time-frequency domain analyses will be examined to identify potential sEMG and biomechanical biomarkers.",[128,129,27,130],"Aging","Foot Muscle Dysfunction","Age-Related Muscle Weakness",[132,133,134,135],"older adults, physical activity, interactive computer games, biomarkers, electrophysiology, biomedical signal processing","Older adults","Biomedical signal processing","Physical activity","2026-08-09",{"date":107,"type":43},{"date":139,"type":43},"2026-06-01",{"date":141,"type":21},"2027-12-30",{"name":143,"class":77},"Tarsus University",{"id":145,"slug":146,"hasResults":12,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":157,"conditions":158,"keywords":163,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":78},"100651334","phase-2-hmb-plus-vitamin-d-to-preserve-muscle-in-older-adults-starting-semaglutide-100651334","NCT07760948","HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide","Preserving the Metabolic Engine: HMB Supplementation to Combat Iatrogenic Sarcopenia and Metabolic Adaptation in Older Adults Initiating Semaglutide Therapy","PRESERVE-HMB","Inclusion Criteria:\n\n* Age 65 to 85 years, inclusive.\n* Type 2 diabetes mellitus, defined by HbA1c at or above 6.5% or current use of antihyperglycemic medication.\n* Body mass index at or above 27 kg\u002Fm2.\n* Newly initiating semaglutide as standard clinical care under the direction of a treating clinician.\n* Able to walk 400 meters without assistance; use of a cane is permitted.\n* Able to understand and provide legally effective informed consent.\n* English speaking for the initial study because the consent documents, questionnaires, study-product instructions, safety instructions, and procedure-specific materials are available only in English.\n\nExclusion Criteria:\n\n* Estimated glomerular filtration rate below 45 mL\u002Fmin\u002F1.73 m2.\n* Use of HMB, creatine, or high-dose whey protein supplements within the previous 3 months.\n* Weight change greater than 5% during the previous 3 months.\n* Recent fracture within the previous 6 months.\n* Neuromuscular disease, including Parkinson disease, or another condition that would interfere with study outcomes or safe participation.\n* Chronic corticosteroid use.\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.\n* History of pancreatitis.\n* Smoking more than 7 cigarettes per day.\n* Previous malabsorptive or restrictive intestinal surgery or a malabsorptive syndrome.\n* Pregnancy or breastfeeding.\n* Recent history of neoplasia within the previous 5 years, as defined by the protocol.\n* Other active inflammatory conditions or neuromuscular disorders that could interfere with study outcomes or safety.\n* Serum 25-hydroxyvitamin D below 15 ng\u002FmL.\n* Any medical, functional, laboratory, medication-related, or safety condition that the investigator determines makes study participation unsafe or prevents completion of essential procedures.","85 Years",{"count":154,"type":21},90,[156],"PHASE2","This randomized, double-blind, placebo-controlled trial will evaluate whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants will receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6. Secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, resting metabolic rate, metabolic measures, and whole-body quantitative computed tomography. An optional mechanistic substudy of up to 36 participants will include D3-creatine dilution, nonradioactive stable isotope infusions, repeated blood sampling, a standardized meal, breath sampling, and vastus lateralis muscle biopsies at baseline and month 6.",[159,27,160,161,162],"Type 2 Diabetes Mellitus (T2DM)","Obesity","Muscle Loss","Older Adults",[164,165,166,167,168,169,170,171,172,173,174,175,176,177],"semaglutide","GLP-1 receptor agonist","beta-hydroxy-beta-methylbutyrate","HMB","calcium-HMB","vitamin D3","appendicular lean mass","metabolic adaptation","resting metabolic rate","skeletal muscle","older adults","D3-creatine","muscle protein synthesis","muscle protein breakdown","NOT_YET_RECRUITING","2026-08-07",{"date":68,"type":43},{"date":182,"type":21},"2026-12-01",{"date":184,"type":21},"2030-11",{"name":186,"class":77},"Vanderbilt University Medical Center",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":17,"minAge":195,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":78},"100626547","early-phase-1-sarcopenia-in-chronic-kidney-disease-ckd-patients-100626547","NCT07437053","Sarcopenia in Chronic Kidney Disease (CKD) Patients","Branched-chain Amino Acids to Improve Sarcopenia in Patients With Advanced Chronic Kidney Disease (BOOST-CKD)","BOOST_CKD","Inclusion Criteria:\n\n1. Ability of participant to understand and the willingness to sign a written informed consent document.\n2. Males and females of age 45-75 yrs\n3. Hand grip strength of \\\u003C26 kg for male and \\\u003C16 kg for female\n4. Documented diagnosis of estimated glomerular filtration rate (eGFR) of ≤15 mL\u002Fmin\u002F1.73 m2, based on CKD-EPI serum-creatinine based formula in the past ≥3 months in absence of acute kidney injury.\n5. Not on dialysis and is not expected to initiate dialysis or any kidney replacement therapy in next 4 months\n6. Receiving standard of care including dietary recommendation for diabetes, hypertension, CKD, and other comorbidities\n7. Patients who are on an SGLT2-i or GLP-1 agonist should be on a stable dose for at least 3 months prior randomization, with no dose adjustments expected in the next 4 months\n8. Serum HCO3 concentration 20-29 mmol\u002FL based on two consecutive recent routine labs\n9. HbA1c 7-9% based on most recent routine lab\n10. Serum albumin ≥3.8 g\u002FdL based on most recent routine lab\n11. Blood hemoglobin ≥10 g\u002FdL based on most recent routine lab\n12. Willingness to adhere to lifestyle management, including diet and exercise as recommended by care providers, and to the study intervention, procedures, and regimen.\n\nExclusion Criteria:\n\n1. Any known history of hypersensitivity\u002Fintolerance to valine or specific amino acids\n2. Any condition that may indicate the individual is not \"metabolically stable\" which may include active infection, currently on systemic antibiotic, hospitalization within 2 weeks on consenting, active malignancy, on immunosuppressive agents, and unexplained significant weight loss during the past 3 months\n3. With a cardiac pacemaker and\u002For an implantable cardioverter-defibrillator\n4. Significant arthritis prohibiting strength test and walk gait speed test\n5. Significant comorbidities including heart failure (NY Class III or IV), neurological disorders, HIV AIDS, etiology of CKD other than diabetes and hypertension, or any condition that could compromise the subject's ability to study procedures as judged by study clinician\n6. Currently taking any protein supplements\n7. Pregnant, lactating, childbearing women\n8. History of Maple syrup urine disease (MSUD)\n9. Scheduled for kidney transplantation or dialysis in next 4 months\n10. Current participation in another interventional trial\n11. Documented noncompliance with regard to clinic visits, medications, and lifestyle management.\n12. Documentation of current or history of substance abuse.","45 Years","75 Years",{"count":198,"type":21},20,[200],"EARLY_PHASE1","Sarcopenia, or loss of muscle and strength is common in patients with poor kidney function. Although a high protein diet is generally recommended for sarcopenia, patients with poor kidney function are advised to follow a low-protein diet. In this study, we will evaluate the practicality and potential benefits of two different amino acids (molecules that form proteins) in improving sarcopenia in patients with advanced kidney disease.\n\nThe study aims to improve muscle mass and strength. All study procedures are free of cost and do not require significant time commitment. You will have time to ask questions and discuss the study with your family, primary care physician, and your kidney doctor to make the decision if this is right study for you to participate in.",[203,27],"Chronic Kidney Disease",[205,206,207],"Valine","Essential amino acid","Metabolic effects",{"date":107,"type":43},{"date":210,"type":21},"2026-08-24",{"date":212,"type":21},"2027-10-30",{"name":214,"class":77},"The University of Texas Health Science Center at San Antonio",{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":78},"100651194","regional-nerve-block-for-upper-extremity-surgery-in-patients-with-sarcopenia-100651194","NCT07757984","Regional Nerve Block for Upper Extremity Surgery in Patients With Sarcopenia","Inclusion Criteria:\n\n* Age\\>=50 years old\n* ASA I-III\n* Receiving upper limb surgery under general anesthesia\n\nExclusion Criteria:\n\n* Severe cognitive impairment or inability to cooperate with pain and motor assessment\n* Pre-existing neuropathy of the musculocutaneous, median, radial or ulnar nerve\n* (for nerve block group) Contraindications to regional nerve blockade",{"count":222,"type":21},150,"The goal of this observational study is to learn about the impact of sarcopenia (muscle loss) on the efficacy of regional nerve blocks and postoperative recovery in patients undergoing upper extremity surgery. The main questions it aims to answer are:\n\n1. Does sarcopenia affect the onset time and success rate of peripheral nerve blocks?\n2. How does sarcopenia influence postoperative pain control and opioid consumption compared to patients receiving pure general anesthesia?\n\nParticipants will undergo a preoperative muscle assessment, which includes a chair stand test and a brief ultrasound of the thigh muscle. Researchers will then observe and record their nerve block onset time (if applicable), postoperative pain scores, and recovery metrics during their hospital stay up to postoperative day 2.",[27,225],"Nerve Block","2026-08-06",{"date":107,"type":43},{"date":229,"type":21},"2026-09-01",{"date":231,"type":21},"2028-08-31",{"name":233,"class":77},"Chang Gung Memorial Hospital",{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":243,"conditions":244,"keywords":247,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":260,"leadSponsor":262,"locationsCount":78},"100650733","gnri-and-rectus-femoris-muscle-thickness-in-older-patients-undergoing-hip-fracture-surgery-100650733","NCT07751692","GNRI and Rectus Femoris Muscle Thickness in Older Patients Undergoing Hip Fracture Surgery","Prognostic Value of the Geriatric Nutritional Risk Index and Ultrasonographic Rectus Femoris Muscle Thickness in Older Patients Undergoing Hip Fracture Surgery: A Prospective Observational Study","Inclusion Criteria:\n\n* Age 65 years or older\n* Scheduled to undergo surgical treatment for hip fracture\n* Provision of informed consent by the participant or, when applicable, a legally authorized representative\n\nExclusion Criteria:\n\n* Pathological fracture or fracture related to malignancy\n* Advanced neuromuscular disease\n* Active infection\n* Planned revision surgery\n* Lower limb amputation or severe deformity preventing rectus femoris muscle thickness measurement\n* Inability to obtain informed consent from the participant or a legally authorized representative",{"count":242,"type":21},120,"This prospective observational study will evaluate whether nutritional risk and reduced muscle mass are associated with postoperative outcomes in adults aged 65 years or older undergoing surgery for hip fracture.\n\nNutritional risk will be assessed using the Geriatric Nutritional Risk Index (GNRI), which is calculated from routine preoperative serum albumin, body weight, and ideal body weight. Rectus femoris muscle thickness will be measured before surgery using a brief, noninvasive ultrasound examination of the non-fractured thigh.\n\nParticipants will receive routine clinical care, and no treatment or anesthesia method will be assigned by the study. Clinical information will be collected from hospital records, including postoperative length of hospital stay, surgical site infection, and mortality. Survival status will be evaluated at 30 and 90 days after surgery using hospital records and\u002For telephone follow-up.",[245,96,27,246],"Hip Fracture","Postoperative Complications",[248,249,250,251,252,253,254,255,256,257],"Geriatric Nutritional Risk Index","Rectus Femoris Muscle Thickness","Muscle Ultrasound","Geriatric Hip Fracture","Nutritional Risk","Postoperative Length of Stay","Surgical Site Infection","Prognostic Factors","30-Day Mortality","90-Day Mortality",{"date":179,"type":43},{"date":72,"type":21},{"date":261,"type":21},"2027-06",{"name":263,"class":77},"Fatih Sultan Mehmet Training and Research Hospital",{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":284},"100612695","malnutrition-screening-study-100612695","NCT07256925","Malnutrition Screening Study","LEVEL-UP Turkish Adult Outpatient Screening Study","Inclusion Criteria:\n\n* Participant has voluntarily signed and dated an informed consent form (ICF), approved by an Independent Ethics Committee (IEC)\u002FInstitutional Review Board (IRB), and provided other applicable privacy regulation authorization (if applicable) prior to any participation in the study.\n* Participant is ≥ 18 years of age who attend hospital clinics (medical and radiation oncology, neurology, and geriatrics clinics) as an outpatient for any reason.\n\nExclusion Criteria:\n\n* NA",{"count":272,"type":21},7500,"This is a non-interventional, cross-sectional, non-randomized, observational study to screen for the risk of malnutrition and sarcopenia in outpatients aged 18 and over who attend hospital clinics for any reason in Turkey.",[275,27],"Malnutrition, Calorie",{"date":179,"type":43},{"date":278,"type":43},"2026-01-12",{"date":280,"type":21},"2027-04",{"name":282,"class":283},"Abbott Nutrition","INDUSTRY",69,{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":292,"sex":17,"minAge":59,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":309,"leadSponsor":311,"locationsCount":78},"100650526","hb05p-on-muscle-health-100650526","NCT07749118","HB05P on Muscle Health","The Effect of HB05P Supplementation on Muscle Strength Improvement: A Randomized, Double-blind, Controlled Preliminary Clinical Trial (HB05P-Muscle Trial)","Inclusion Criteria:\n\n* Men or women aged 50 to under 80 years\n* Meeting the 2025 Asian Working Group for Sarcopenia (AWGS) criteria for sarcopenia (low muscle mass and low handgrip strength) or possible sarcopenia (low muscle mass with either low handgrip strength or low physical performance). Low muscle mass is defined as ASM\u002Fheight\\^2 measured by bioelectrical impedance analysis below 7.6 kg\u002Fm\\^2 for men and below 5.7 kg\u002Fm\\^2 for women aged 50 to 64 years, and below 7.0 kg\u002Fm\\^2 for men and below 5.7 kg\u002Fm\\^2 for women aged 65 years or older. Low handgrip strength is defined as the maximum value of the dominant hand at or below the following thresholds: 34.5 kg for men and 22.0 kg for women aged 50 to 54 years; 33.5 kg for men and 21.5 kg for women aged 55 to 59 years; 31.0 kg for men and 20.0 kg for women aged 60 to 64 years; 29.0 kg for men and 19.0 kg for women aged 65 to 69 years; 27.5 kg for men and 18.0 kg for women aged 70 to 74 years; 26.0 kg for men and 16.8 kg for women aged 75 to 79 years. Low physical performance is defined as more than 10 seconds on the 5-time chair stand test of the Short Physical Performance Battery for participants aged 50 to 64 years, and more than 12 seconds for those aged 65 years or older.\n* Not having participated in a commercial exercise program or performed regular resistance exercise 2 or more times per week within the 3 months before study participation\n* Physically able to participate in the standardized resistance exercise program provided from the start of the study at least 3 times per week, and willing to comply with it\n* Having received a full explanation of the purpose and procedures of the study and having voluntarily provided written informed consent\n\nExclusion Criteria:\n\n* Short Physical Performance Battery total score of 3 or less\n* Cachexia or unintentional weight loss of 5 percent or more within the past 3 months\n* History of fracture or musculoskeletal surgery within the past 6 months\n* Musculoskeletal or functional limitation that precludes isokinetic strength testing or performance of the standardized exercise program (for example, severe osteoarthritis or rheumatoid arthritis)\n* Uncontrolled or clinically unstable endocrine disease (for example, Cushing syndrome or adrenal insufficiency)\n* Severe respiratory disease (COPD GOLD stage III to IV or long-term oxygen therapy)\n* Uncontrolled hypertension (systolic blood pressure 160 mmHg or higher, or diastolic blood pressure 100 mmHg or higher), uncontrolled diabetes mellitus (fasting glucose 160 mg\u002FdL or higher), or uncontrolled thyroid disease\n* Major cardiovascular or cerebrovascular event within the past 6 months (acute myocardial infarction, stroke, unstable angina, percutaneous coronary intervention, or coronary artery bypass grafting)\n* History of malignancy within 3 years before screening or currently receiving anticancer treatment, except malignancies with negligible risk of metastasis or death such as adequately treated non-melanoma skin cancer or carcinoma in situ\n* AST or ALT greater than 3 times the upper limit of normal at screening\n* Serum creatinine greater than 2 times the upper limit of normal at screening\n* History of gastrointestinal surgery or gastrointestinal disease that may affect absorption of the study food, except simple appendectomy or hernia repair\n* Known hypersensitivity to the active ingredient or any component of the study food\n* Use of systemic antibiotics or bowel preparation agents within 2 weeks before screening\n* Intake of probiotics, prebiotics, or lactic acid bacteria or fermented milk products 4 or more times per week within 2 weeks before screening, excluding fermented foods included in a regular diet\n* Continuous use of protein supplements or muscle-related health functional foods within 1 month before screening\n* Use of medications that may affect muscle mass or muscle strength within 3 months before screening, including systemic corticosteroids (oral or injectable), testosterone, growth hormone preparations, selective androgen receptor modulators, and anti-obesity drugs\n* Severe alcohol use disorder according to DSM-5 diagnostic criteria\n* Continuous use of psychiatric medication for schizophrenia, bipolar disorder, or severe major depressive disorder, excluding intermittent medication for sleep disturbance\n* Participation in another clinical trial within 3 months before screening, or current participation in another clinical trial\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the study period\n* Any other condition that, in the judgment of the principal investigator, may affect the safety of the participant or the integrity of the study results",true,"79 Years",{"count":295,"type":21},80,[24],"The purpose of this pilot study is to evaluate whether HB05P, a health functional food ingredient containing pasteurized Akkermansia muciniphila HB05, improves muscle strength, and to evaluate its safety.\n\nThis is a randomized, double-blind, placebo-controlled, parallel-group, single-center study. A total of 80 adults aged 50 to under 80 years who meet the 2025 Asian Working Group for Sarcopenia (AWGS) criteria for sarcopenia or possible sarcopenia will be randomly assigned in a 1:1 ratio to the test group or the control group.\n\nParticipants will take one 430 mg hard capsule once daily with water after breakfast for 168 days (24 weeks). The test capsule contains 150 mg of HB05P (3 x 10\\^10 cells per day); the control capsule contains microcrystalline cellulose and is identical in appearance and packaging. All participants are asked to perform 30 to 60 minutes of walking and resistance exercise at least 3 times per week throughout the study and to keep an exercise diary and an intake diary.\n\nThe primary outcome is the change from baseline in peak torque per body weight (Nm\u002Fkg) of the quadriceps and hamstrings, measured with an isokinetic dynamometer at an angular velocity of 60 degrees per second and averaged across the left and right sides. Secondary outcomes include average power, muscle strength, muscle mass measured by dual-energy X-ray absorptiometry, handgrip strength, Short Physical Performance Battery scores, muscle-related blood markers, and quality of life. Efficacy and safety are assessed at baseline (Day 0), Week 12 (Day 84), and Week 24 (Day 168).",[27,299],"Possible Sarcopenia",[301,302,303,304,305],"Akkermansia muciniphila","Postbiotic","Muscle strength","Skeletal muscle mass","Functional food","2026-08-05",{"date":105,"type":43},{"date":229,"type":21},{"date":310,"type":21},"2027-06-30",{"name":312,"class":77},"Pusan National University Yangsan Hospital",{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":17,"minAge":320,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":78},"100638563","phase-2-clinical-study-of-tj0113-capsule-in-the-treatment-of-patients-with-sarcopenia-100638563","NCT07620938","Clinical Study of TJ0113 Capsule in the Treatment of Patients With Sarcopenia","A Randomized, Double-Blind, Multicenter, Placebo Parallel-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of TJ0113 Capsule in the Treatment of Patients With Sarcopenia","Inclusion Criteria:\n\n1. Voluntarily participate in the clinical study and sign the informed consent form (ICF), willing and able to comply with the study protocol (e.g., able to understand and complete questionnaires, adhere to visit schedules, and use study medication);\n2. Male or female aged ≥60 years at the time of signing the ICF;\n3. Meet the diagnostic criteria of the \"Guideline for Diagnosis and Treatment of Sarcopenia in China (2024 Edition)\", specifically as follows:\n\n   3.1Low muscle mass: DXA measurement of muscle mass \\\u003C 7.0 kg\u002Fm2 in males \u002F \\\u003C 5.4 kg\u002Fm2 in females, or BIA measurement of muscle mass \\\u003C 7.0 kg\u002Fm2 in males \u002F \\\u003C 5.7 kg\u002Fm2 in females; 3.2Low muscle strength (grip strength \\\u003C 28.0 kg in males, grip strength \\\u003C 18.0 kg in females); and\u002For physical dysfunction (walking speed in free state \\\u003C 1 m\u002Fs, or 5 Times Sit-to-Stand Test ≥ 12 s, or Short Physical Performance Battery score ≤ 9).\n4. Able to complete the 400-meter Walk Test within 15 minutes without sitting down, leaning against a wall, requiring assistance from others, or using a walker or cane.\n5. Participants of childbearing potential (including spouses of male participants) must have no plans for pregnancy or sperm donation from the screening period until 6 months after the last dose, and must be willing to use at least one effective contraceptive method (see Appendix 1) for contraception.\n6. Individuals whose results from comprehensive physical examination, vital signs, routine laboratory tests (complete blood count, blood biochemistry, urinalysis, coagulation), 12-lead electrocardiogram, chest X-ray, etc., are normal, or although abnormal, are determined by the investigator to be in the following condition: conditions considered stable and controlled by the investigator,planned during the studypatients with chronic diseases (e.g., hypertension and hyperlipidemia controlled within normal range, well-controlled non-insulin-dependent diabetes, etc.) who are taking medication regularly according to the established regimen and whose condition does not affect the study observation indicators after enrollment; abnormal items in screening tests determined by the investigator to be related to the patient's age or the aforementioned chronic diseases.\n\nExclusion Criteria:\n\n1. Any medical condition that may interfere with adequate participation in the trial, including but not limited to the following: a history of epilepsy or complications, a history of hemolytic anemia, pulmonary embolism, or malignant tumors, or a positive tumor marker test result during the screening period that is assessed by the investigator as clinically significant;\n2. New York Heart Association (NYHA) Class III or above congestive heart failure, unstable angina pectoris, acute myocardial infarction, hemorrhagic stroke, ischemic stroke (including transient ischemic attack) occurring within 6 months prior to screening; or Within 6 months prior to screening, undergone percutaneous coronary intervention, coronary artery bypass grafting, or cardiac valve repair\u002Freplacement; or at the time of screening, the presence of ventricular tachycardia, ventricular fibrillation, polymorphic ventricular tachycardia, etc., as judged by the investigator that may be life-threatening or lead to hemodynamic instability arrhythmia;\n3. Personal or family history of long QT syndrome, family history of sudden death before the age of 40 in first-degree relatives (parents, children, and siblings); and\u002For personal history of unexplained syncope within 1 year prior to screening; and\u002For based on resting ECG results at screening: QT interval corrected for heart rate using Fridericia's formula, QTcF \\> 450 ms (males), QTcF \\> 470 ms (females) \\[Fridericia's formula: QTc = QT\u002F(RR0.33), where RR represents the standard heart rate value, calculated as 60 divided by heart rate\\];\n4. Presence of uncontrolled hypertension at screening, defined as systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg (confirmed before randomization);\n5. During screening chest pain, severe dyspnea, or other safety issues occurring during functional testing (e.g., 400-meter walk test), as assessed by the investigator to be unsuitable for participation in this study;\n6. Presence of clinically significant hepatic impairment, defined as total bilirubin (TBIL) \\>2× upper limit of normal (ULN) and\u002For alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\>2× ULN;\n7. Presence of clinically significant renal impairment (creatinine clearance rate \\[Ccr\\] \\\u003C30 mL\u002Fmin). The formula for calculating Ccr is provided in Appendix II;\n8. Suffering from underlying diseases that may cause malnutrition, including chronic diarrhea (defined as a significant increase in bowel movement frequency compared to usual habits \\[\\>3 times\u002Fday\\], lasting \\>4 weeks, or recurrent diarrhea with intervals of 2-4 weeks), Crohn's disease and other digestive system diseases, neuropsychiatric disorders such as anorexia nervosa, uncontrolled diabetes mellitus (fasting blood glucose \\>8.3 mmol\u002FL after treatment) and other metabolic diseases, chronic obstructive pulmonary disease (Modified Medical Research Council Dyspnea Scale \\[MMRC\\] score ≥2), chronic heart failure (diagnosed according to the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure, 2024, NYHA class III or above), and other chronic wasting diseases, which, in the investigator's judgment, make the patient unsuitable for participation in this study;\n9. Individuals with neuromuscular diseases (e.g., Parkinson's disease), or other muscle system disorders such as muscular atrophy or myositis that could affect the diagnostic parameters of sarcopenia;\n10. Patients with implanted cardiac pacemakers or stents who, upon investigator assessment, are deemed unsuitable for participation in this study (Note: BIA testing is not recommended for individuals with implanted electronic devices such as cardiac pacemakers);\n11. Individuals with physical disabilities or injuries\u002Fsurgeries to the upper or lower limbswithin 3 months prior to screeningthat may affect grip strength or gait speed measurements;\n12. Participants with a history of severe allergy, or known hypersensitivity\u002Fallergic reaction or intolerance to any component of the investigational product;\n13. Use of drugs affecting bone and muscle metabolism (bisphosphonates, estrogens, calcitonin, teriparatide, long-term oral or injectable corticosteroids \\[use for ≥2 weeks or requiring long-term use as determined by the investigator\\]) within 7 days or 5 half-lives prior to screening, whichever is longer (Note: Patients who have received a stable dose of denosumab for ≥6 months prior to screening and do not intend to change the dose during the study are permitted for enrollment; patients who plan to receive stable doses of bone mineralization promoters such as calcium, vitamin D, active vitamin D and its analogs \\[including calcitriol, alfacalcidol, etc.\\] within 4 weeks prior to the first dose and during the study period are permitted for enrollment);\n14. Evidence of alcohol abuse (average weekly consumption of ≥14 units of alcohol, where 1 unit ≈ 360 mL of beer, or 45 mL of liquor, or 150 mL of wine) or alcohol dependence within 6 months before screening, which in the investigator's opinion would interfere with the participant's understanding or completion of the study;\n15. Patients with a history of drug dependence\u002Fsubstance abuse within the past 1 year prior to screening;\n16. Positive for hepatitis B surface antigen (HBsAg) with HBV-DNA ≥ 1000 copies\u002FmL or 200 IU\u002FmL, or positive for hepatitis C virus (HCV) antibody with HCV RNA ≥ the lower limit of detection of the study site, or positive for human immunodeficiency virus (HIV) antibody, or positive for Treponema pallidum antibody at screening;\n17. Participation in a clinical study involving administration of an investigational drug, device, or surgery within 3 months or 5 half-lives (whichever is longer) before the first dose;\n18. Inability to swallow oral medications, or, in the investigator's judgment, presence of any condition that could significantly affect drug absorption, distribution, metabolism, or excretion (e.g., active enteropathy, partial or complete intestinal obstruction, chronic diarrhea), or any condition that could pose a risk to the participant;\n19. Subjects who have a history of organ transplantation (excluding corneal transplantation);\n20. Donated blood (including blood products) (including blood products) or experienced blood loss ≥400 mL within 1 month prior to screening, or received a blood transfusion (including blood products);\n21. Pregnant or breastfeeding women;\n22. Other reasons deemed by the investigator that the participant has poor compliance or is unsuitable for participation in this study.","60 Years",{"count":322,"type":21},204,[156],"This study is a randomized, double-blind, multicenter, placebo parallel-controlled Phase II clinical study designed to evaluate the clinical efficacy and safety of TJ0113 Capsule in patients with sarcopenia. The entire study plans to enroll 204 participants with sarcopenia. Eligible participants will be stratified by age (\\\u003C 70 years or ≥ 70 years to ≤ 80 years or \\> 80 years) and block-randomized in a 1:1:1:1 ratio into 4 groups (TJ0113 Capsule 100 mg dose group; TJ0113 Capsule 200 mg dose group; TJ0113 Capsule 400 mg dose group; placebo group), with 51 participants per group. Participants in the placebo group will then be re-randomized in a 1:1:1 ratio to the respective dose groups (100 mg, 200 mg, and 400 mg). After randomization, study participants will receive continuous oral administration for 26 weeks with efficacy and safety evaluations, followed by a 1-week follow-up period after the end of treatment.",[27],"2026-08-03",{"date":306,"type":43},{"date":329,"type":43},"2026-06-12",{"date":331,"type":21},"2027-10-22",{"name":333,"class":283},"Hangzhou PhecdaMed Co., Ltd.",{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":78},"100475926","adverse-outcomes-and-mortality-in-liver-transplant-100475926","NCT05477277","Adverse Outcomes and Mortality in Liver Transplant","Inclusion Criteria:\n\n1. All patients with end-stage liver disease undergoing evaluation for liver transplantation\n2. Patient clinically indicated for MRI during transplant candidacy evaluation\n3. Adult\n\nExclusion Criteria:\n\n1\\. Contra indication to MRI",{"count":341,"type":21},100,[24],"Prospective natural history pilot study to explore the link between muscle composition using an MRI-based Muscle Assessment Score (MAsS) and adverse outcomes in liver transplant candidates.",[345,27,346,347],"End Stage Liver DIsease","Sarcopenic Obesity","Cirrhosis",{"date":306,"type":43},{"date":350,"type":43},"2022-11-02",{"date":352,"type":21},"2027-12-31",{"name":354,"class":77},"Mayo Clinic",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":17,"minAge":363,"maxAge":122,"enrollmentInfo":364,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":367,"conditions":368,"keywords":371,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":78},"100650354","phase-2-glp-1-agonists-for-lung-function-improvement-and-muscle-restoration-in-copd-100650354","NCT07747805","GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD","GLIMR COPD: GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD","GLIMR COPD","Inclusion Criteria:\n\n* Age 40-80 years\n* Diagnosis of chronic obstructive pulmonary disease (COPD) with post-bronchodilator FEV₁\u002FFVC \\\u003C 0.70\n* GOLD stage 1-3 COPD (FEV₁ \\>30% predicted)\n* Former smoker with a smoking history of at least 10 pack-years\n* Body mass index (BMI) ≥27 kg\u002Fm² with at least one weight-related comorbidity (e.g., prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) or BMI 30-40 kg\u002Fm²\n* Able and willing to provide written informed consent\n* Able to comply with study procedures and follow-up visits\n\nExclusion Criteria:\n\n* Type 2 diabetes mellitus (HbA1c \\> 6.5%)\n* Pregnancy or breastfeeding\n* Coagulopathy, defined as INR \\> 1.4 or platelet count \\\u003C80,000\u002FμL\n* Active malignancy, including lung cancer\n* Use of medications known to significantly alter muscle protein metabolism within 6 weeks of enrollment (e.g., oral corticosteroids, tamoxifen, high-dose estrogen, testosterone)\n* Personal or family history of medullary thyroid carcinoma\n* Multiple endocrine neoplasia syndrome type 2 (MEN2)\n* Known hypersensitivity or contraindication to tirzepatide or its components\n* History of pancreatitis\n* Severe gastrointestinal disease that, in the opinion of the investigator, would increase risk from study participation\n* Significant diabetic retinopathy\n* Clinically significant renal impairment\n* Clinically significant gallbladder disease\n* Current treatment with a DPP-4 inhibitor\n* COPD exacerbation within 60 days prior to enrollment\n* Participation in pulmonary rehabilitation within 2 weeks prior to enrollment\n* Any medical, psychiatric, or social condition that, in the opinion of the investigators, may interfere with study participation, adherence to study procedures, or participant safety","40 Years",{"count":365,"type":21},30,[156],"Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammation, obesity-related metabolic dysfunction, skeletal muscle impairment, and progressive decline in lung function. While obesity has historically been viewed as protective in COPD, emerging evidence suggests that excess adiposity and adipokine dysregulation, particularly elevated leptin levels, contribute to chronic inflammation, impaired muscle function, and worse clinical outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated anti-inflammatory, metabolic, and potential muscle-preserving effects beyond weight loss, making them promising therapeutic candidates for COPD.\n\nThe GLIMR COPD study is a prospective, randomized, controlled pilot trial designed to evaluate the effects of tirzepatide on lung function, skeletal muscle health, inflammation, and body composition in overweight and obese adults with COPD. Thirty participants will be enrolled at the Cleveland Clinic COPD Center, including 20 participants receiving tirzepatide and 10 age- and sex-matched control participants. Study participants will be followed for 12 months with assessments performed at screening, baseline, 6 months, and 12 months. Tirzepatide-treated participants will undergo standard dose escalation to a maintenance dose of 2.4 mg weekly.\n\nThe primary objective is to determine the effect of GLP-1 receptor agonist therapy on skeletal muscle function and physiology over 12 months. Secondary objectives include evaluating changes in body composition, systemic inflammation, adipokine signaling, immune function, pulmonary physiology, physical performance, and treatment tolerability.\n\nThe study is built around three mechanistic aims. First, we will characterize the effects of GLP-1 therapy on systemic inflammation and immune dysregulation using longitudinal blood-based proteomic analyses and adipokine measurements, including leptin and adiponectin. Second, we will investigate the impact of GLP-1 therapy on skeletal muscle mitochondrial function and fatty acid oxidation using muscle biopsies obtained at baseline and 12 months, combined with high-resolution respirometry, transcriptomics, metabolomics, and proteomics. Third, we will assess changes in clinical outcomes including lung function, body composition, muscle strength, and physical performance.\n\nParticipants will undergo comprehensive phenotyping that includes spirometry, respiratory muscle strength testing, six-minute walk testing, handgrip strength, sit-to-stand testing, body composition assessment, diaphragm ultrasound, and non-contrast CT imaging of the lungs and thighs. Blood samples will be collected for biomarker, proteomic, metabolomic, genomic, and immunologic analyses. Vastus lateralis muscle biopsies will be performed at baseline and study completion to evaluate mitochondrial bioenergetics and molecular pathways associated with muscle remodeling.\n\nEligible participants will be adults aged 40-80 years with COPD, a smoking history of at least 10 pack-years, and overweight or obesity. Individuals with diabetes, active malignancy, recent COPD exacerbations, contraindications to tirzepatide, or conditions that could interfere with study participation will be excluded.\n\nThis pilot study is designed to generate critical mechanistic and clinical data regarding the role of GLP-1 receptor agonists in COPD. Findings will help define the relationships among obesity, adipokine signaling, systemic inflammation, skeletal muscle dysfunction, and lung disease progression, while providing preliminary efficacy estimates to support the design of a future multicenter randomized clinical trial evaluating GLP-1 therapy as a novel treatment strategy for COPD.",[369,370,27],"COPD","Obesity & Overweight",[369,30,372],"obesity","2026-07-31",{"date":306,"type":43},{"date":376,"type":21},"2026-08-28",{"date":378,"type":21},"2029-08-15",{"name":380,"class":77},"The Cleveland Clinic",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":17,"minAge":59,"maxAge":196,"enrollmentInfo":388,"targetDuration":4,"studyType":22,"phases":390,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":78},"100627305","optimizing-adaptive-intensive-behavioral-therapy-for-obesity-during-the-transition-to-older-adulthood-100627305","NCT07446907","Optimizing Adaptive Intensive Behavioral Therapy for Obesity During the Transition to Older Adulthood","Optimizing Adaptive Intensive Behavioral Therapy for Obesity During the Transition to Older Adulthood: A Sequential Multiple Assignment Randomized Trial","Inclusion Criteria:\n\n* Male or female sex\n* all racial and ethnic groups\n* BMI: 30-50 kg\u002Fm2\n* age 50-75 years\n* postmenopausal status for ≥1 y if female sex\n\nExclusion Criteria:\n\n* \\\u003C3 months stable use of other medications affecting body weight or appetite\n* \\>450 pounds (due to weight limitations of the DXA)\n* indication or previous diagnosis of sarcopenia\n* existing kidney disease\n* current binge eating disorder, anorexia, or bulimia\n* untreated hyper- or hypothyroidism, cancer (except basal cell), gastrointestinal disorders affecting food intake or nutrient absorption; any other medical condition, as determined by the study physician, precluding a HP diet and\u002For daily exercise",{"count":389,"type":21},250,[24],"To test adaptive intensive behavioral therapy strategies comprising dietary patterns with varying amounts of protein and including supplemental protein or resistance exercise training for promoting weight loss and attenuating lean mass loss in adults aged 50-75 with obesity.",[370,27],[160,27],{"date":326,"type":43},{"date":396,"type":21},"2026-09",{"date":398,"type":21},"2031-06-30",{"name":400,"class":77},"University of Alabama at Birmingham",{"id":402,"slug":403,"hasResults":12,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":408,"targetDuration":4,"studyType":22,"phases":409,"briefSummary":410,"conditions":411,"keywords":412,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":420},"100598492","phase-2-a-study-of-amc6156-in-people-with-sarcopenia-100598492","NCT07072195","A Study of AMC6156 in People With Sarcopenia","A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia","Inclusion Criteria:\n\n* Voluntary participation with written informed consent\n* Male ≥ 65 years or postmenopausal female\n* Diagnosed with sarcopenia:\n* ASM \\\u003C 7.0 kg\u002Fm² (men) or \\\u003C 5.4 kg\u002Fm² (women)\n* Plus low handgrip strength or SPPB ≤ 9\n* MNA screening score ≥ 8\n* Body weight ≥ 35 kg, BMI between 15-30 kg\u002Fm²\n* Willing and able to follow exercise and nutrition guidance\n\nExclusion Criteria:\n\n* Allergy to investigational drug\n* History of GI bleeding, ulcers, or severe liver\u002Fkidney\u002Fheart disease\n* QTc ≥ 450 ms with symptoms\n* Severe COPD, uncontrolled diabetes or thyroid disease\n* Diseases causing cachexia or muscle wasting (e.g., ALS, Parkinson's)\n* Vitamin D deficiency (\\\u003C10 ng\u002FmL), hemoglobin \\\u003C10 g\u002FdL\n* Severe psychiatric disorders or MMSE \\\u003C 21\n* Inability to walk or recent fracture\u002Fsurgery affecting mobility\n* Use of prohibited medications or recent participation in other clinical trials\n* Investigator deems the subject unsuitable for the study",{"count":295,"type":21},[156],"This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.",[28,27],[30],{"date":326,"type":43},{"date":415,"type":43},"2025-07-01",{"date":417,"type":21},"2027-02-15",{"name":419,"class":283},"Animuscure Inc.",4,{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":17,"minAge":320,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":22,"phases":430,"briefSummary":431,"conditions":432,"keywords":436,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":78},"100619531","the-effect-of-volunteer-engaged-lifestyle-optimisation-via-icope-on-sarcopenia-in-older-adults-velo-s-100619531","NCT07345832","The Effect of Volunteer-Engaged Lifestyle Optimisation Via ICOPE on Sarcopenia in Older Adults (VELO-S)","The Effect of Volunteer-Engaged Lifestyle Optimisation Via ICOPE on Sarcopenia in Older Adults (VELO-S): A Randomised Controlled Trial","Inclusion Criteria:\n\n1. aged 60 or above\n2. Pseudo-Sarcopenia as indicated by a score on SARC-CaIF ≥11, OR sarcopenia according relative BIA-based appendicular skeletal mass\u002F height (Men: \\\u003C7 kg\u002Fm2; women: \\\u003C5.7 kg\u002Fm2), OR handgrip strength on dominant hand (male \\\u003C28 kg, female \\\u003C18 kg) (Chen et al., 2025)\n3. the ability to use a smartphone, electronic tablet, or computer\n4. consent to participate\n\nExclusion Criteria:\n\n1. having medical conditions contradictory to physical activity including unstable cardiovascular and orthopaedic conditions\n2. engaging in other structured health promotion program involving physical activity and nutritional enhancement",{"count":429,"type":21},200,[24],"Sarcopenia prevention and management are highly prioritised goals in the Healthy Ageing agenda. The study aims to: 1) evaluate the effects of the digital-enhanced, volunteer-engaged collaborative care pathway to improve sarcopenia, reduce fall risk, and increase health-related quality of life (HRQL) among community-dwelling older adults with risk of, or diagnosed with, sarcopenia; 2) evaluate whether the volunteers who received health coach capacity training and supported the intervention experienced health benefits across time; 3) explore the engagement experiences and perceived effects of elderly participants with sarcopenia during the program; 4) evaluate the intervention implementation process and effects from the perspectives of social care workers.",[27,28,433,434,435,95],"Fall Prevention in Healthy Aging","Frailty Syndrome","Malnutrition Elderly",[30,437,438,439,440,441,442],"elderly","frailty","fall prevention","malnutrition","health-related quality of life","digital intervention","2026-07-30",{"date":373,"type":43},{"date":446,"type":43},"2026-02-01",{"date":448,"type":21},"2027-09-30",{"name":450,"class":77},"The University of Hong Kong",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":459,"briefSummary":460,"conditions":461,"keywords":464,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":78},"100649281","effects-of-a-community-based-multicomponent-physical-exercise-program-on-physical-function-frailty-and-sarcopenia-in-older-adults-from-the-municipality-of-santoa-a-quasi-experimental-study-100649281","NCT07732478","Effects of a Community-based Multicomponent Physical Exercise Program on Physical Function, Frailty, and Sarcopenia in Older Adults From the Municipality of Santoña: a Quasi-experimental Study.","Inclusion Criteria:\n\n* Age 65 years or older\n* Independent, community-dwelling (not institutionalized)\n* Barthel Index score ≥ 90 points (no significant disability)\n* Timed Up and Go (TUG) test ≥ 10 seconds\n* Short Physical Performance Battery (SPPB) score below 12 points (indicating possible frailty)\n* Fall risk indicated by at least one of the following: one fall in the past year requiring assistance, more than one fall without assistance, TUG \\> 20 seconds, or gait speed over 6 meters \\> 7.50 seconds\n* Reduced grip strength: below 27 kg (men) or below 16 kg (women), or more than 15 seconds to complete 5 chair stands\n* Voluntary signed informed consent\n\nExclusion Criteria:\n\n* Terminal illness\n* Residing in a nursing home\n* Diagnosed with, or under investigation for, moderate to severe cognitive impairment\n* Unstable cardiovascular disease\n* Acute infectious disease\n* Uncontrolled hypertension (systolic \\> 180 mmHg or diastolic \\> 110 mmHg)\n* Uncontrolled diabetes\n* Advanced organ failure\n* Disabling musculoskeletal condition",{"count":458,"type":21},300,[24],"This study evaluates the effects of a community-based multicomponent exercise program on physical function, frailty, and sarcopenia in older adults living in the municipality of Santoña (Cantabria, Spain). The exercise program is organized and delivered by the Santoña Town Council as part of its public health services for older residents and is not created for research purposes; it will continue regardless of the outcome of this study. Researchers are only evaluating participants who voluntarily agree to be assessed before and after each 36-week cycle of the program, over four consecutive academic years (2026-2030). The main question this study aims to answer is whether continued participation in this real-world, community-based multicomponent exercise program (based on the Vivifrail model) leads to meaningful improvements in physical function, muscle strength, and cardiorespiratory capacity, and helps reverse indicators of frailty and sarcopenia in independent, community-dwelling older adults. Participants will complete functional and physical tests, including balance, gait speed, chair-stand performance, handgrip strength, and a 6-minute walk test, at the start and end of each 36-week exercise cycle. No blood or biological samples will be collected.",[462,463,27],"Frailty\u002FSarcopenia","Frailty in Older Adults",[465,466,133,467,468,27,303,469,470,471],"Multicomponent exercise","Community-based exercise program","Physical function","Frailty prevention","Cardiorespiratory fitness","Fall prevention","Real-world effectiveness","2026-07-28",{"date":443,"type":43},{"date":475,"type":21},"2026-10-01",{"date":477,"type":21},"2030-07-31",{"name":479,"class":77},"Universidad de Granada",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":17,"minAge":363,"maxAge":122,"enrollmentInfo":488,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":490,"conditions":491,"keywords":494,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":78},"100649268","relationship-between-ultrasonographic-quadriceps-muscle-thickness-and-sarcopenia-markers-handgrip-strength-sarc-f-and-kinesiophobia-in-stroke-patients-100649268","NCT07734506","RELATIONSHIP BETWEEN ULTRASONOGRAPHIC QUADRICEPS MUSCLE THICKNESS AND SARCOPENIA MARKERS (HANDGRIP STRENGTH, SARC-F) AND KINESIOPHOBIA IN STROKE PATIENTS","EVALUATION OF THE RELATIONSHIP BETWEEN ULTRASONOGRAPHICALLY MEASURED QUADRICEPS MUSCLE THICKNESS AND SARCOPENIA MARKERS (HANDGRIP STRENGTH, SARC-F) AND KINESIOPHOBIA IN STROKE PATIENTS","QMSK","Inclusion Criteria:\n\n* Chronic stroke duration between 6 months and 2 years\n* Ischemic stroke type\n* Age between 40-80 years\n* Brunnstrom lower extremity motor stage ≥3, ambulatory\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Hemorrhagic stroke\n* Stroke onset more than 2 years prior\n* Inflammatory arthritis or other rheumatologic disease\n* History of knee trauma\n* Pre-stroke neurological gait disorder\n* Recurrent stroke\n* Lower extremity amputation\n* Knee joint contracture",{"count":489,"type":21},50,"The aim of this study is to evaluate the relationship between ultrasonography-measured quadriceps muscle thickness and the sarcopenia markers SARC-F questionnaire and handgrip strength in patients diagnosed with ischemic stroke. In addition, the relationship between quadriceps muscle thickness and the level of kinesiophobia will be quantitatively assessed.\n\nThis study is a cross-sectional clinical study conducted between August 1, 2025, and August 1, 2026, at the Physical Medicine and Rehabilitation Clinic of the University of Health Sciences İstanbul Physical Medicine and Rehabilitation Training and Research Hospital. Fifty volunteer participants with ischemic stroke and a lower-extremity Brunnstrom motor stage of 3 or higher, who presented to the clinic during the study period, were included.\n\nBilateral quadriceps femoris muscle thickness, including the rectus femoris and vastus intermedius muscles, was measured using ultrasonography. The SARC-F questionnaire was used to assess sarcopenia risk, handgrip strength measurement was used to evaluate muscle strength, and the Tampa Scale for Kinesiophobia was used to determine the level of kinesiophobia. Motor recovery stage was assessed using the Brunnstrom Staging system; motor and cognitive independence were assessed using the Functional Independence Measure; walking independence was assessed using the Functional Ambulation Scale; and independence in activities of daily living was assessed using the Barthel Index of Activities of Daily Living.\n\nBecause balance impairment, muscle weakness, and limited mobility are common after stroke, physical performance tests may be difficult to administer safely and consistently in this patient population. Therefore, the relationship between quadriceps muscle thickness and physical performance tests was not evaluated in this study. The Chair Stand Test, which requires repeated sit-to-stand movements as well as adequate balance and lower-extremity muscle strength, was also not included because it may increase the risk of falls in patients with limited mobility.\n\nThis study aims to demonstrate the clinical potential of ultrasonography in the assessment of post-stroke sarcopenia and to support a more holistic approach to stroke rehabilitation planning that considers both physical and psychological factors.",[492,27,493],"Stroke","Kinesiophobia",[495,496,27,497,498,493,499],"Quadriceps Muscle Thickness","Ultrasonography","SARC-F","Handgrip Strength","Stroke Rehabilitation","2026-07-27",{"date":502,"type":43},"2026-07-29",{"date":504,"type":43},"2025-08-01",{"date":506,"type":21},"2026-08-01",{"name":508,"class":50},"Istanbul Physical Medicine Rehabilitation Training and Research Hospital",{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":520,"conditions":521,"keywords":522,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":78},"100541419","phase-3-effect-of-ketosteril-on-sarcopenia-in-patients-with-chronic-kidney-disease-100541419","NCT06329622","Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease","Ketosteril Sarcopenia Chronic Kidney Disease","Inclusion Criteria:\n\n1. Meet the diagnostic criteria for CKD stage 3-4 (15 ≤eGFR\\\u003C60 ml\u002F(min\\*1.73m2)) in the 2012 Kidney Disease Improving Global Outcomes (KDIGO) guideline.\n2. Sarcopenia should be diagnosed According to the 2019 Asian Working Group for Sarcopenia (AWGS) diagnostic criteria for sarcopenia: ① Muscle strength: grip strength (\\\u003C 28 kg for males, \\\u003C 18 kg for females); ② Physical function: is assessed by walking speed over 6 m (\\\u003C 1.0 m\u002Fs) or five-repetition sit-to-stand test (5STS) (≥ 12 s) or recommended short physical performance battery (SPPB) (≤ 9); ③ Artificial skeletal muscle (ASM) of extremities: Bioelectrical impedance analyzer (BIA) (\\\u003C 7.0 kg\u002Fm2 for males and \\\u003C 5.7 kg\u002Fm2 for females). On the basis of meeting criteria ③, sarcopenia can be diagnosed if at least one of the first two items is met.\n3. Patient can walk normally.\n4. Provide the written informed consent.\n\nExclusion Criteria:\n\n1. Patients with diabetes.\n2. Obese\u002Foverweight patients (body mass index\\>25 kg\u002Fm2)\n3. Had previously received renal replacement therapy (including kidney transplantation, hemodialysis, peritoneal dialysis).\n4. Patients with new cardiovascular events, uncontrolled acute or chronic cardiac failure within 3 months.\n5. Patients with acute infection (C-reactive protein\\>10 mg\u002FL) or acute exacerbation of chronic diseases that is not under control within 3 months.\n6. Patients with cerebrovascular events, severe liver disease, malignant tumor and multiple organ failure.\n7. Patients with osteoarthritis, metabolic bone disease, osteonecrosis of the femoral head, hemiplegia and cognitive dysfunction.\n8. Patients with hypercalcemia and amino acid metabolism disorder.\n9. Those who are allergic to the active ingredients or other excipients of the Ketosteril.\n10. Patients with poor compliance, unable to follow the study requirements for diet control.\n11. Participated in other interventional clinical trials within 30 days before this study.",{"count":517,"type":21},58,[519],"PHASE3","The investigators hypothesize that Ketosteril can improve sarcopenia in patients with renal disease without increasing the burden on the kidneys and causing deterioration of renal function. Therefore, this study intends to take patients with CKD stage 3-4 and sarcopenia as the research object, give Ketosteril intervention or not to patients on the base of low-protein diet, and clarify the clinical benefits of Ketosteril prescription for improving sarcopenia in patients with CKD.",[203,27],[523,30],"CKD","2026-07-25",{"date":472,"type":43},{"date":527,"type":43},"2024-05-01",{"date":529,"type":21},"2028-06-30",{"name":531,"class":77},"Huashan Hospital",{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":538,"eligibilityCriteria":539,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":22,"phases":541,"briefSummary":542,"conditions":543,"keywords":545,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":78},"100649404","sarcopenia-screening-in-advanced-coxarthrosis-the-sarco-cox-study-100649404","NCT07734129","Sarcopenia Screening in Advanced Coxarthrosis: The SARCO-COX Study","Efficacy of a Sarcopenia Screening Program in Subjects With Advanced Coxarthrosis. SARCO-COX Randomized Intervention Study","SARCO-COX","Inclusion Criteria:\n\n* Subjects age \\>= 65 years of age\n* Previous diagnosis of advanced hip osteoarthritis.\n* Patients who are on the surgical waiting list for total joint replacement hip.\n* Barthel Index \\> 80 points.\n* That they will undergo surgery at the Regional University Hospital of Malaga.\n\nExclusion Criteria:\n\n* Patients who refuse to accept and sign the informed consent form surgical intervention.\n* Patients who refuse to accept and sign the informed consent form participation in the study.\n* Subjects diagnosed with immunodeficiency or undergoing immunosuppressive treatment.\n* Subjects diagnosed with inflammatory or hematological disease.\n* Subjects with coagulation disorders.\n* Subjects with lung disease, heart disease or unstable high blood pressure.\n* Subjects diagnosed with neurodegenerative disease that prevents them from performing physical exercise.\n* Subjects with psychiatric pathology that prevents the performance of physical exercise and adherence to treatment.",{"count":222,"type":21},[24],"The SARCO-COX study evaluates whether screening for sarcopenia (loss of muscle strength and mass) in adults aged 65 years or older with advanced hip osteoarthritis, followed by a structured postoperative exercise program, improves recovery after total hip replacement surgery compared with standard care.\n\nParticipants will undergo assessments of muscle strength, muscle mass, physical function, pain, and quality of life before surgery and during follow-up. Blood samples and a small muscle biopsy obtained during the planned surgery will be analyzed to study biomarkers related to muscle health.\n\nA total of 150 people are expected to participate in this study. Participants will be divided into three groups:\n\n* Group 1: People with sarcopenia who will take part in an exercise programme following surgery.\n* Group 2: People with sarcopenia who will receive the usual care and follow-up after their surgery.\n* Group 3: people without sarcopenia who are undergoing surgery and will receive the usual care and follow-up.\n\nThe study aims to determine whether early identification and targeted rehabilitation of sarcopenia can improve functional outcomes and quality of life after hip replacement.",[27,544],"Coxarthrosis",[303,546,547,27,548],"Biomarkers","Exercise therapy","Hip arthrosis","2026-07-24",{"date":502,"type":43},{"date":552,"type":21},"2026-07-01",{"date":554,"type":21},"2029-09-01",{"name":556,"class":77},"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":292,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":565,"conditions":566,"keywords":569,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":574,"startDateStruct":575,"completionDateStruct":576,"leadSponsor":578,"locationsCount":78},"100633808","muscle-aging-phenotypes-in-childhood-cancer-survivors-100633808","NCT07531498","Muscle Aging Phenotypes in Childhood Cancer Survivors","Inclusion Criteria:\n\n* Age 18 years old or older at time of consent and enrolled in SJLIFE.\n* Participant (100 per group for a total of 400) is\u002Fhas:\n* Group 1: No cancer history\n* Group 2: Age and sex specific relative lean mass z-score of less than -0.5 OR age and sex specific hand grip or isokinetic (60 degrees\u002Fsec) quadriceps strength z-score of \\\u003C-0.5 AND exposure to a peripheral neurotoxin.\n* Group 3: Age and sex specific relative lean mass z-score of less than -0.5 OR age and sex specific hand grip or isokinetic (60 degrees\u002Fsec) quadriceps strength z-score of \\\u003C-0.5 AND NOT exposed to a peripheral neurotoxin.\n* Group 4: Age and sex specific relative lean mass z-score of less than -0.5 AND age and sex specific hand grip strength or isokinetic (60 degrees\u002Fsec) quadriceps strength z-score of \\\u003C-0.5 REGARDLESS of exposure status.\n* Participant or legal guardian is able and willing to give informed consent.\n\nExclusion Criteria:\n\n* Presence of implanted medical devices or metal that would interfere with MRI or MRS.\n* Female Participant is pregnant.\n* Body weight exceeding 300 pounds, due to MRI restrictions.\n* Inability to lie flat on his\u002Fher back for 90 minutes or longer for MRI.\n* Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent.\n* Presence of known radiation-induced nerve injury.\n* Prescence of pre-existing neurologic (non-cancer related) or who develop chronic neurologic disorders (i.e. Charcot Marie Tooth Disease, Downs, congenital brain injury).\n* Participation on a lifestyle or medication clinical trial within the past 1 year.",{"count":564,"type":21},533,"Childhood cancer survivors experience premature declines in muscle mass, strength, and physical function that contribute to morbidity and early mortality. The biological mechanisms driving these impairments are heterogeneous and poorly understood. This observational study aims to characterize distinct muscle health endotypes in adult survivors of childhood cancer using advanced imaging, neuromuscular testing, and functional assessment. Survivors with reduced muscle health and community controls will undergo multimodal magnetic resonance imaging and spectroscopy, nerve conduction studies, surface electromyography, body composition assessment, and physical performance testing during a single study visit integrated into an ongoing cohort evaluation. Identifying mechanistic endotypes of impaired muscle health will support development of targeted interventions to preserve function and improve long-term outcomes in childhood cancer survivors.\n\nPrimary Objective:\n\n\\- Characterize reduced muscle health endotypes in childhood cancer survivors.\n\nSecondary Objective:\n\n\\- Identify specific treatment and lifestyle related risk factors for each reduced muscle health endotype.\n\nExploratory Objective:\n\n\\- Host germline genetics will be associated with specific muscle endotypes.",[567,568,27],"Muscle Weakness","Low Muscle Mass",[570,571,572,573],"Childhood Cancer Survivors","Adult Survivors of Childhood Cancer","Neuromuscular Function","Muscle Health",{"date":472,"type":43},{"date":475,"type":21},{"date":577,"type":21},"2031-05",{"name":579,"class":77},"St. Jude Children's Research Hospital",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":585,"acronym":586,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":588,"targetDuration":4,"studyType":22,"phases":590,"briefSummary":591,"conditions":592,"keywords":4,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":596,"completionDateStruct":597,"leadSponsor":599,"locationsCount":78},"100649189","exercise-intervention-for-breast-cancer-patients-with-sarcopenia-100649189","NCT07732101","Exercise Intervention for Breast Cancer Patients With Sarcopenia","Development and Evaluation of an Exercise Intervention Program for Breast Cancer Patients With Sarcopenia During Rehabilitation","EX-BCSarc","Inclusion Criteria:\n\nFemale, aged ≥18 years;\n\nPathologically confirmed diagnosis of breast cancer, having completed primary treatment (surgery, chemotherapy, radiotherapy, etc.) and currently in the rehabilitation phase (≥3 months after treatment completion);\n\nMeet sarcopenia diagnostic criteria assessed by trained researchers: for women aged ≥65 years, ASMI \\\u003C 0.57 and handgrip strength \\\u003C 18 kg; for women aged \\\u003C64 years, ASMI \\\u003C 0.63 and handgrip strength \\\u003C 20 kg;\n\nProvide informed consent and voluntarily participate in the study;\n\nHave basic communication and comprehension abilities.\n\nExclusion Criteria:\n\nHistory of psychiatric disorders or consciousness impairment;\n\nPresence of exercise contraindications including severe cardiac, hepatic, or renal insufficiency, bone metastases, or uncontrolled hypertension;\n\nMajor surgery or severe trauma within the past 3 months;\n\nInvoluntary weight loss \\>5% within the past 3 months, or presence of active progressive tumor burden (e.g., imaging evidence of significant metastasis or receiving palliative chemotherapy), suggesting tumor-driven cachexia;\n\nCurrently participating in other exercise intervention studies or having completed other exercise programs within the past 6 months;\n\nRefusal of randomization.",{"count":589,"type":21},104,[24],"Sarcopenia is a common yet underrecognized complication in breast cancer survivors during rehabilitation, characterized by loss of muscle mass, reduced muscle strength, and impaired physical function, which adversely affects quality of life and long-term outcomes. Exercise has been identified as a promising non-pharmacological intervention for sarcopenia; however, evidence-based exercise programs specifically tailored for breast cancer patients with sarcopenia remain limited.\n\nThis study aims to develop and evaluate a 12-week exercise intervention program (\"Exercise for Muscle Health\") for breast cancer patients with sarcopenia during rehabilitation. A randomized controlled trial will be conducted to assess the effectiveness of the intervention. A total of 104 eligible participants will be randomly assigned in a 1:1 ratio to either the intervention group or the control group. The intervention group will receive a 12-week structured exercise program combined with health education, while the control group will receive routine rehabilitation care with general physical activity recommendations.\n\nThe primary outcomes include changes in appendicular skeletal muscle mass index (ASMI), handgrip strength, Short Physical Performance Battery (SPPB) score, and physical fitness (2-Minute Step Test and 30-second Chair-Stand Test). Secondary outcomes include sarcopenia-related knowledge, cancer self-efficacy, social support, anxiety, fatigue, and quality of life. Assessments will be conducted at baseline (T0), mid-intervention (week 6, T1), immediately post-intervention (week 12, T2), and 3 months post-intervention (T3).\n\nThe hypothesis is that the 12-week \"Exercise for Muscle Health\" program will significantly improve muscle mass, muscle strength, and physical function compared to routine care, and will be feasible, acceptable, and safe for breast cancer patients with sarcopenia during rehabilitation.",[27,593],"Breast Cancer","2026-07-23",{"date":472,"type":43},{"date":229,"type":21},{"date":598,"type":21},"2027-04-20",{"name":600,"class":77},"Capital Medical University",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":17,"minAge":607,"maxAge":4,"enrollmentInfo":608,"targetDuration":4,"studyType":22,"phases":610,"briefSummary":611,"conditions":612,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":614,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":618,"locationsCount":78},"100647943","exploration-on-the-relationship-between-distinct-sarcopenia-traditional-chinese-medicine-body-constitution-and-circadian-rhythm-patterns-of-older-adults-and-impact-of-acupoint-stimulated-interventions-100647943","NCT07715721","Exploration on the Relationship Between Distinct Sarcopenia, Traditional Chinese Medicine Body Constitution, and Circadian Rhythm Patterns of Older Adults and Impact of Acupoint-stimulated Interventions","Inclusion Criteria:\n\n* Participants must be able to understand and sign the informed consent form.\n* For the geriatric cohorts: Individuals aged 65 and above.\n* For the adult cohort: Individuals aged between 20 and 64.\n* For the sleep disturbance cohorts: Presenting with a Pittsburgh Sleep Quality Index (PSQI) score of 5 or higher.\n* For the sarcopenia cohort: Evaluated and diagnosed with sarcopenia according to standard geriatric metrics.\n\nExclusion Criteria:\n\n* Individuals with severe cognitive impairment, advanced dementia, or inability to communicate and follow instructions.\n* Individuals with unstable medical conditions, acute cardiovascular events, or severe systemic diseases that preclude safe participation in exercise programs.\n* Individuals with open wounds, active infections, or fractures at the targeted acupoint areas.\n* Any other conditions that, in the judgment of the investigator, would jeopardize candidate safety or compliance.","20 Years",{"count":609,"type":21},360,[24],"The purpose of this study is to evaluate the clinical efficacy and impact of digital\u002Fremote courses combining traditional Chinese medicine (TCM) acupoint-stimulated interventions, health education, and exercise on sarcopenia and sleep disturbances across distinct age groups. By integrating multidisciplinary expertise encompassing TCM, geriatric medicine, geriatric health, community medicine, and epidemiology at Ministry of Health and Welfare Tainan Hospital, this project aims to explore the correlations among sarcopenia, sleep conditions, and TCM body constitution, while evaluating the feasibility of incorporating the simplified Body Constitution Questionnaire (BCQ) into anti-frailty screenings to establish an evidence-based, TCM-integrated intervention model. A total of at least 360 participants will be recruited at Ministry of Health and Welfare Tainan Hospital across two distinct operational phases. In the first phase, a comprehensive cross-sectional assessment will be conducted on 300 older adults aged 65 and above to establish a geriatric TCM body constitution database, utilizing 7-day actigraphy, scientific tongue and pulse diagnosis, the BCQ, and standard geriatric functional assessment scales (including SARC-F, Fried frailty index, ADL, IADL, WHOQOL-BREF, EQ-5D, mini nutritional assessment, ISI, PSQI, and ECOG score), with eligible and consenting participants referred for overnight polysomnography (PSG) based on physician assessment. In the second phase, longitudinal interventional trials will be executed with 180 participants divided into three specific cohorts. The sarcopenia cohort, comprising 60 older adults aged 65 and above, will undergo a 3-month intervention combining acupoint massage and the Vivifrail exercise program, with data evaluated at baseline, month 1, and month 3, followed by a final tracking period extending to month 4. The geriatric sleep disturbance cohort (60 older adults aged 65 and above) and the adult sleep disturbance cohort (60 younger adults aged 20-64), all presenting with a Pittsburgh Sleep Quality Index (PSQI) score of 5 or higher, will participate in a 2-week curriculum consisting of sleep-related self-acupoint massage and sleep hygiene education, with clinical follow-ups scheduled at baseline, week 2, and week 6, a final tracking assessment at week 7, and intervention compliance monitoring conducted at week 3.",[27,613],"Sleep Wake Disorders",{"date":500,"type":43},{"date":616,"type":43},"2023-05-19",{"date":352,"type":21},{"name":619,"class":77},"Tainan Hospital, Ministry of Health and Welfare",{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":4,"eligibilityCriteria":626,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":627,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":629,"conditions":630,"keywords":633,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":637,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":78},"100631415","multimodal-nutritional-and-sarcopenia-assessment-for-risk-stratification-in-lung-cancer-surgery-100631415","NCT07500376","Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery","Prognostic Value of Multimodal Nutritional Status and Sarcopenia Assessment for Postoperative Risk Stratification in Patients Undergoing Lung Cancer Surgery: A Prospective Cohort Study","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients undergoing anatomical lung resection (lobectomy or segmentectomy) for primary lung cancer\n* Availability of preoperative thoracic computed tomography (CT) within 30 days before surgery\n* Completion of preoperative nutritional assessment and ultrasonographic muscle measurements\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Receipt of neoadjuvant chemotherapy, immunotherapy, or radiotherapy\n* Emergency surgery\n* Pneumonectomy\n* Combined resection of another organ during the same procedure\n* Inadequate or non-evaluable imaging or measurement data\n* Immunosuppressive therapy or presence of advanced\u002Fmetastatic disease\n* Significant thoracic deformity or prior conditions interfering with muscle measurements\n* Refusal or inability to provide informed consent",{"count":628,"type":21},142,"This prospective observational cohort study aims to evaluate the prognostic value of multimodal nutritional status and sarcopenia assessment in patients undergoing lung cancer surgery. Postoperative complications, mortality, and prolonged hospital stay remain major clinical concerns in thoracic surgery. Although malnutrition and sarcopenia are recognized as important determinants of surgical outcomes, their combined and multidimensional evaluation has not been sufficiently studied.\n\nAdult patients undergoing anatomical lung resection for primary lung cancer will be included. Nutritional status will be assessed using serum biomarkers, inflammatory indices, and validated clinical nutritional scores. Sarcopenia will be evaluated using computed tomography-based muscle mass and density measurements, as well as ultrasonographic muscle thickness.\n\nThese parameters will be analyzed in relation to postoperative complications, intensive care unit (ICU) requirement, length of hospital stay, and mortality. Multivariable analyses will be performed to identify independent predictors, and a combined risk stratification model will be developed.\n\nThis study aims to improve preoperative risk assessment and to support personalized perioperative management strategies, including identification of patients who may benefit from targeted nutritional optimization and prehabilitation.",[631,27,632],"Lung Cancer (Non-Small Cell)","Malnutrition Severe",[634,30,635,440,636],"lung cancer surgery","nutritional status","risk stratification",{"date":549,"type":43},{"date":639,"type":43},"2026-03-15",{"date":641,"type":21},"2027-03-15",{"name":643,"class":77},"Ondokuz Mayıs University",{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":648,"acronym":649,"eligibilityCriteria":650,"healthyVolunteers":292,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":652,"conditions":653,"keywords":655,"overallStatus":178,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":661,"completionDateStruct":662,"leadSponsor":664,"locationsCount":78},"100648773","stride-strength-of-the-calf-muscles-and-their-role-in-declining-effectiveness-of-movement-with-aging-100648773","NCT07726498","STRIDE: Strength of The Calf Muscles and Their Role In Declining Effectiveness of Movement With Aging","STRIDE","Inclusion Criteria:\n\n* Participant is able and willing to provide informed consent to participate in the study\n* Aged 18 years or over\n* Ambulatory status: able to walk independently with or without aids\n* Able to attend clinic\n\nExclusion Criteria:\n\n* Participant is unwilling or unable to give informed consent.\n* Palliative\u002F end of life\n* Moderate to severe communication difficulties\u002F cognitive function\n* Immobile\n* Lower limb surgery within the last 6 months\n* Recent lower limb fracture\n* Unstable cardiopulmonary conditions\n* Severe impairments of vision or vestibular system\n* Lower limb corticosteroid injection within the last 6 months\n* No restriction on language",{"count":429,"type":21},"The calf muscles (plantarflexors) are the most important muscles for walking, running and daily activities. Weakness of these muscles through aging and disease significantly impact a person's ability to walk and complete daily activities. By assessing calf strength, it is possible to identify people at risk of falls, and a condition called sarcopenia (which means loss of muscle mass, strength and function). Unfortunately, most of the studies that have examined this have used specialist equipment unavailable to hospital staff. Our study aims to use commercially available equipment to explore the relationship between plantarflexor muscle strength and physical performance in adults living with or without sarcopenia, including those at risk of it. The study will determine if stronger\u002Fweaker calf muscles associated with sarcopenia influence the ability to walk and do things more easily. We will complete strength tests of the calf, thigh and hand, assess walking using a special camera system, use an ultrasound scan to look at the Achilles tendon, use a scan to look at how stiff your calf muscles are, assess your body composition, complete a physical performance test and some questionnaires. Each participant will complete the measures during one clinic visit",[27,128,654,95],"Muscle Weakness or Atrophy",[656,27,128,657,658],"Plantarflexors","Weakness","Multi-morbidity","2026-07-22",{"date":549,"type":43},{"date":72,"type":21},{"date":663,"type":21},"2028-02-29",{"name":665,"class":77},"University of Leicester"]